The BRCA Mastr Plus Dx assay and Mastr Reporter software identifies mutations in the coding regions of the BRCA1 and BRCA2 genes
At the German Society of Human Genetics annual meeting in Bochum, Berlin's Atlas Biolabs talked about its first experience with the Clarigo test.
Agilent plans to pay approximately €68 million in cash, and the deal is expected to be completed by mid-January.
The company currently offers target amplification assays for diagnostic use and clinical research that are based on a proprietary multiplex PCR technology.
The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.
The Belgian company is also developing new tests and applications with its Multiplex Amplification of Specific Targets for Resequencing technology.
The BRCA Tumor MASTR Plus Dx assay identifies somatic mutations in the BRCA1 and BRCA2 genes in FFPE tumor tissue from ovarian cancer patients.
The non-invasive test is designed to detect chromosomal abnormalities in the fetus to reduce the number of pregnant women undergoing invasive procedures.
The companies are taking the CE-IVD route as opposed to the LDT model in the US due to Europe's distributed prenatal testing market and lower regulatory hurdles.
NEW YORK (GenomeWeb) – Researchers affiliated with the University of Antwerp and Antwerp University Hospital have partnered with molecular diagnostics firm Multiplicom to develop a test to help identify individuals at risk for sudden cardiac death.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.